Recon: FDA declines to review Soligenix’s lymphoma drug; GSK pulls out of COVID deal with Vir
ReconJoanne S. Eglovitch
Biologics/ biosimilars/ vaccinesDiagnostics/IVDsEuropeGlobalMedical DevicesNorth AmericaPharmaceuticalsRegulatory Intelligence/Policy